Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wei Yu who wrote (11701)	11/25/1997 6:05:00 PM
From: Sunny Jim	Read Replies (3) \| Respond to of 32384

Wei, Looks like LGND is struggling to staunch the bleeding in the stock price by re-issuing some old news. Still Long LGND and holding nose.

To: Wei Yu who wrote (11701)	11/25/1997 8:11:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Wei,, The new release doesn't contain anything new. However, the deal was not complete until ALRI was disolved and rights to LGND's compounds moved to LGND and rights to AGN's compounds moved to them. Now its all systems go. I expect LGND to announce the selection of the LLY compound and I expect it to be SRGN's IL-2 fusion protein. I think LGND will be able to apply it to cancer as well as psoriasis and it will be approved for cancer (CTCL) soon. It's revenue stream will be small by LLY standards, but sufficiently large enough to make LGND profitable in 1999. I also expect this green light to lead to the three popular press articles that I have mentioned in the past.